Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Elvira Mora-Casterá"'
Autor:
Irene Serrano-Gonzalo, Laura López de Frutos, Carlos Lahoz-Gil, Francisco Delgado-Mateos, María Ángeles Fernández-Galán, Montserrat Morales-Conejo, María Victoria Calle-Gordo, Daiana Ibarretxe-Gerediaga, Andrés Madinaveitia-Ochoa, Antonio Albarracin-Arraigosa, José Balanzat-Muñoz, Patricia Correcher-Medina, Luis Javier García-Frade, Jesús María Hernández-Rivas, Francesca Labbadia, Jesus Miguel López-Dupla, María Luisa Lozano-Almela, Elvira Mora-Casterá, María Soledad Noya-Pereira, María Ángeles Ruíz-Guinaldo, María del Mar Tormo-Díaz, Isidro Vitoria-Miñana, Isidro Arévalo-Vargas, Marcio Andrade-Campos, Pilar Giraldo
Publikováno v:
Orphanet Journal of Rare Diseases, Vol 18, Iss 1, Pp 1-12 (2023)
Abstract Background The availability of multiple treatments for type 1 Gaucher disease increases the need for real-life studies to evaluate treatment efficacy and safety and provide clinicians with more information to choose the best personalized the
Externí odkaz:
https://doaj.org/article/117cc15479cb4170b8e7211100fa9146
Autor:
Lucía Pérez-Lamas, Alejandro Luna, Concepcion Boque, María Alicia Senin, Blanca Xicoy, Pilar Giraldo, Raul Perez Lopez, Concepción Ruiz Nuño, Natalia De las Heras, Elvira Mora Casterá, Carmen Garcia-Hernandez, Adrian Segura Diaz, Juan Luis Steegmann, Patricia Velez Tenza, Fermin Sanchez-Guijo, Ana Maria Garcia-Noblejas Moya, Juan Antonio Juan Vera Goñi, Melania Moreno Vega, Alberto Alvarez-Larran, Montse Cortes, Manuel Perez Encinas, Luis Serrano, Anna Angona, Ana Rosell, Sunil Lakhwani, Mercedes Colorado, Elena Ramila, Carlos Cervero, Beatriz Cuevas, Lucia Villalon Blanco, Juan Carlos Hernandez Boluda, Antonio Paz Coll, Valle Gómez García de Soria, Maria Jose Fernández, Luis Felipe Casado, Juan Manuel Alonso-Dominguez, Maria Magdalena Anguita Arance, Patricia Carrascosa Mastell, Araceli Salamanca Cuenca, Antonio Jiménez-Velasco, María José Ramírez, Miguel López Esteban, Magdalena Sierra Pacho, Marta Santaliestra, Olga Alda Alvarez, Raquel de Paz, Valentín García Gutiérrez
Publikováno v:
Blood. 140:3925-3928
Autor:
Maria Julia Montoro Gómez, Laura Palomo, Pablo Vidal, Francisco Fuster-Tormo, Esperanza Such, Margarita Ortega, Teresa González, Felix Lopez-Cadenas, Sara Garcia-Avila, Nieves Garcia-Gisbert, Elvira Mora Casterá, Eugenia Rivero, Francesc Bosch, Andrés Jerez, Maria Diez-Campelo, Francesc Solé, David Valcárcel
Publikováno v:
Blood. 140:6949-6951
Autor:
Lucía Pérez-Lamas, Alejandro Luna, Concepción Boque, Blanca Xicoy, Pilar Giraldo, Raúl Pérez López, Concepción Ruiz Nuño, Natalia De las Heras, Elvira Mora Casterá, Javier López Marín, Adrián Segura Díaz, Valle Gómez, Patricia Vélez Tenza, Magdalena Sierra Pacho, Juan Antonio Vera Goñi, Melania Moreno Vega, Alberto Alvarez-Larrán, Montse Cortés, Manuel Pérez Encinas, Patricia Carrascosa Mastell, Anna Angona, Ana Rosell, Sunil Lakhwani, Mercedes Colorado, Elena Ramila, Carlos Cervero, Beatriz Cuevas, Lucía Villalón Blanco, Raquel de Paz, Antonio Paz Coll, María José Fernández, Luis Felipe Casado, Juan Manuel Alonso-Domínguez, María Magdalena Anguita Arance, Araceli Salamanca Cuenca, Antonio Jiménez-Velasco, Santiago Osorio Prendes, Marta Santaliestra, María José Lis Chulvi, Juan Carlos Hernández-Boluda, Valentín García-Gutiérrez
Publikováno v:
Scientia
Cancers
Volume 15
Issue 4
Pages: 1045
Cancers
Volume 15
Issue 4
Pages: 1045
Simple Summary After the recent irruption of asciminib into the therapeutic arsenal for chronic myeloid leukemia, real-life data remain scarce to determine which patients may benefit most from this drug. Data on the efficacy of the drug in real-world
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95d62a6253d555f83c73979b06dacbda
https://hdl.handle.net/11351/9705
https://hdl.handle.net/11351/9705
Autor:
Blanca Xicoy, Peter Valent, Juliana Schwaab, Khalid Shoumariyeh, Enrique Colado, Francesco Olivieri, Annette Schmitt-Graeff, Javier I. Muñoz-González, Andrés C. García-Montero, Georg Greiner, Iván Álvarez-Twose, Carlos Fernandez-Gimenez, Andreas Reiter, Jason Gotlib, María Jara-Acevedo, Ana Gabriela Henriques, Roberta Zanotti, Andrea Mayado, Alba Pérez-Pons, Cecelia Perkins, Wolfgang R. Sperr, Irene Luna, Mohamad Jawhar, Elvira Mora-Casterá, Maria-Helena Bañas, Ilaria Tanasi, Patrizia Bonadonna, Guillermo Martín-Sánchez, Laura Sánchez-Muñoz, Georgina Gener-Ricós, Amanda Nuñez-García, Manuel Jurado-Chacón, Leonor Senent, Justus Duyster, Carolina Caldas, Alberto Orfao
Publikováno v:
Lancet Haematology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Digital.CSIC. Repositorio Institucional del CSIC
LANCET HAEMATOLOGY
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Digital.CSIC. Repositorio Institucional del CSIC
LANCET HAEMATOLOGY
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
[Background]: Several risk stratification models have been proposed in recent years for systemic mastocytosis but have not been directly compared. Here we designed and validated a risk stratification model for progression-free survival (PFS) and over
Autor:
Angeles Escola, Fermín Sánchez-Guijo, Elena Rámila, Elvira Mora Casterá, Juan Carlos Hernandez Boluda, Alejandro Luna, Concepción Boqué, Rocio Fé Bitaube, Valle Gomez, Sunil Lakhwani, Ana García-Noblejas, Melania Moreno Vega, Sara Suarez-Varela, Miguel Sagüés, Valentín García Gutiérrez, Ana Rosell, Luis Serrano, Montse Cortés, Raul Perez Lopez, Juan Luis Steegmann, Ferran Vall-Llovera, Patricia Velez, Antonio Jiménez-Velasco, Carlos Cerveró, Maria Jose Fernández, Mercedes Colorado Araujo, Manuel Mateo Pérez Encinas, Concepción Ruiz Nuño, Antonio Paz Coll, Pilar Giraldo, Natalia de las Heras, Luis Felipe Casado, Araceli Salamanca Cuenca, Lucia Villalon, Beatriz Cuevas, Juan-Manuel Alonso-Domínguez, Carmen Garcia-Hernandez, Lucía Pérez-Lamas, Juan Antonio Juan Vera Goñi, Blanca Xicoy, Patricia Carrascosa Mastell, Alberto Alvarez-Larrán
Publikováno v:
Blood. 138:2563-2563
Introduction: asciminib is a first-in-class STAMP (Specifically Targeting the ABL Myristoyl Pocket) inhibitor that potently inhibits aberrant kinase activity of the BCR-ABL1 oncoprotein via allosteric binding. asciminib has shown high efficacy profil
Autor:
Francisca García, Andres Jerez, Míriam Vara, Itziar Oiartzabal, Marisa Calabuig, Míriam Gutiérrez, Iván Martín, Esperanza Such, Laura Blanco, Rosario Abellán, Teresa González, R. Fernández, Guillermo Sanz, Aroa Irigoyen, Carlos Solano, Blanca Xicoy, Elvira Mora Casterá, Lurdes Zamora, Angela Gil, Rosana Diez, Rosa Collado, Teresa Bernal del Castillo, Mar Tormo, F. López, María José Calasanz, Raquel de Paz, Eva Villamón, Sara Alvarez, Isabel Granada, Alejandro Vivar Sanz
Publikováno v:
Blood. 136:1-2
Introduction : The 20q deletion [del(20q)] is a recurrent chromosomal aberration in myelodysplastic syndromes (MDS) and, as a single abnormality, is associated according to the Revised International Prognostic Scoring System (IPSS-R) with a favorable
Autor:
Joan Bargay, Maria Jose Lys, Margarita Ortega, Mar Tormo, Guillermo Villacampa, Elvira Mora Casterá, Marina Díaz-Beyá, Helena Pomares, Paula Cárcel, Teresa Bernal, Laura Vilorio, David Valcárcel, Merchan Brayan, Antonieta Molero, Maria Julia Montoro, Fernando Ramos, Eugenia Rivero, Andres Jerez, Blanca Xicoy, María Díez-Campelo
Publikováno v:
Blood. 136:9-10
Introduction: Although the IPSS-R stratifies patients with MDS in five risk groups and includes an intermediate-risk group, treatment options are commonly based on the division of the patients into low-risk MDS (LR-MDS) and high-risk MDS (HR-MDS). Ho
Publikováno v:
Blood research
Autor:
Jorge Mora, Maria Laura Fox, Ignacio Gómez-Centurión, Irene García-Cadenas, Carlos Solano, Juan Carlos Hernandez Boluda, Rosalía de la Puerta, Juan-Gonzalo Correa, Santiago Osorio-Prendes, Rafael Hernani, José Luis Piñana, Francisco Cervantes, Nieves Dorado, Veronica Aguilar-Perea, Albert Esquirol, Alberto Alvarez-Larrán, Valentín García Gutiérrez, Montserrat Rovira, Elvira Mora Casterá, Adolfo Saez-Martin, Rodrigo Martino, Ana Benzaquen, Ana A. Martín, Fermín Sánchez-Guijo
Publikováno v:
Blood. 134:5733-5733
Introduction: Allogeneic hematopoietic cell transplantation (allo-HCT) constitutes the only curative treatment for myelofibrosis (MF), but its associated toxicity remains high. Prognostic risk models are widely used in clinical practice to select tho